Watch Point Trust Co lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,137 shares of the medical research company’s stock after buying an additional 1,353 shares during the quarter. Watch Point Trust Co’s holdings in Thermo Fisher Scientific were worth $3,244,000 as of its most recent filing with the SEC.
Several other large investors also recently made changes to their positions in TMO. Arthur M. Cohen & Associates LLC increased its holdings in Thermo Fisher Scientific by 8.9% during the 3rd quarter. Arthur M. Cohen & Associates LLC now owns 4,720 shares of the medical research company’s stock worth $1,375,000 after purchasing an additional 386 shares during the last quarter. Papp L Roy & Associates increased its holdings in Thermo Fisher Scientific by 1.6% during the 3rd quarter. Papp L Roy & Associates now owns 64,087 shares of the medical research company’s stock worth $18,666,000 after purchasing an additional 994 shares during the last quarter. Karp Capital Management Corp increased its holdings in Thermo Fisher Scientific by 0.7% during the 3rd quarter. Karp Capital Management Corp now owns 4,980 shares of the medical research company’s stock worth $1,451,000 after purchasing an additional 35 shares during the last quarter. Bingham Osborn & Scarborough LLC purchased a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $234,000. Finally, Alps Advisors Inc. increased its holdings in Thermo Fisher Scientific by 17.2% during the 3rd quarter. Alps Advisors Inc. now owns 6,623 shares of the medical research company’s stock worth $1,929,000 after purchasing an additional 972 shares during the last quarter. Institutional investors and hedge funds own 88.24% of the company’s stock.
In related news, Director Jim P. Manzi sold 1,833 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $272.93, for a total transaction of $500,280.69. Following the completion of the transaction, the director now owns 28,592 shares in the company, valued at approximately $7,803,614.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 2,271 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $298.00, for a total value of $676,758.00. Following the transaction, the chief executive officer now owns 283,502 shares of the company’s stock, valued at approximately $84,483,596. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,833 shares of company stock valued at $15,299,095. Insiders own 0.45% of the company’s stock.
Several research firms have issued reports on TMO. Needham & Company LLC lifted their price objective on Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $315.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. ValuEngine downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Credit Suisse Group reiterated a “buy” rating and issued a $310.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. Finally, Robert W. Baird lifted their target price on Thermo Fisher Scientific from $305.00 to $319.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $314.45.
Shares of TMO traded up $1.11 during mid-day trading on Friday, hitting $294.65. The stock had a trading volume of 773,005 shares, compared to its average volume of 1,323,858. The company has a market cap of $117.34 billion, a PE ratio of 26.50, a PEG ratio of 1.90 and a beta of 1.14. The company’s fifty day simple moving average is $290.14 and its two-hundred day simple moving average is $283.57. The company has a quick ratio of 1.23, a current ratio of 1.80 and a debt-to-equity ratio of 0.56. Thermo Fisher Scientific Inc. has a fifty-two week low of $208.34 and a fifty-two week high of $306.00.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $2.94 EPS for the quarter, topping the consensus estimate of $2.88 by $0.06. The company had revenue of $6.27 billion during the quarter, compared to analyst estimates of $6.19 billion. Thermo Fisher Scientific had a return on equity of 17.16% and a net margin of 14.24%. The business’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.62 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 12.33 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Tuesday, December 17th will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 6.83%.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.